Enduring Material

- https://journals.sagepub.com/doi/abs/10.1177/24755303231198482

• To understand the comorbidity burden in psoriasis patients with skin of color

Comorbidity Burden in Psoriasis Patients With Skin of Color

• Bruce Strober, MD

• The National Psoriasis Foundation designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Psoriasis is a chronic disease with increased risk of numerous comorbidities. Known differences exist regarding treatment outcomes for psoriasis patients with skin of color. Learn more about comorbidity burden in SOC psoriasis patients vs White patients, as measured by the Charlson Comorbidity Index.

Bruce Strober, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol Myers Squibb, Connect Biopharma, Dermavant, Eli Lilly, Equillium, GlaxoSmithKline, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera, Novar - Consulting - Relationship Has Not Ended
AbbVie, Eli Lilly, Janssen, and Sanofi-Genzyme - Speaking - Relationship Has Not Ended
CorEvitas Psoriasis Registry - co-scientific director - Relationship Has Not Ended
AbbVie, Cara Therapeutics, the CorEvitas Psoriasis Registry, Dermavant, Dermira, and Novartis - investigator - Relationship Has Not Ended
Journal of Psoriasis and Psoriatic Arthritis - editor-in-chief - Relationship Has Not Ended

Sam Koons, NPF Staff, has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:
BMS - Consulting - Relationship Has Ended

Bruce Strober, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• AbbVie, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Immunic Therapeutics, Bristol Myers Squibb, Connect Biopharma, Dermavant, Eli Lilly, Equillium, GlaxoSmithKline, Janssen, LEO Pharma, Maruho, Meiji Seika Pharma, Mindera, Novar - Consulting - Relationship Has Not Ended
• AbbVie, Eli Lilly, Janssen, and Sanofi-Genzyme - Speaking - Relationship Has Not Ended
• CorEvitas Psoriasis Registry - co-scientific director - Relationship Has Not Ended
• AbbVie, Cara Therapeutics, the CorEvitas Psoriasis Registry, Dermavant, Dermira, and Novartis - investigator - Relationship Has Not Ended
• Journal of Psoriasis and Psoriatic Arthritis - editor-in-chief - Relationship Has Not Ended

Any financial relationship that was found to be relevant has been mitigated.

This activity is supported by an independent educational grant from Novartis.

• The National Psoriasis Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

100 %

12/5/2023